Anticoagulation for patients with atrial fibrillation and risk factors for stroke - Warfarin reduces the risk by two thirds, but doctors still aren't prescribing it enough

被引：19

作者：

Connolly, ST ^{[1
]}

机构：

[1] McMaster Univ, Hamilton, ON L8L 2X2, Canada

来源：

BRITISH MEDICAL JOURNAL | 2000年 / 320卷 / 7244期

关键词：

D O I：

10.1136/bmj.320.7244.1219

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1219 / 1220

页数：2

共 8 条

[1]

Blackshear JL, 1996, LANCET, V348, P633

[2] Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation [J].

Howitt, A ;

Armstrong, D .

BMJ-BRITISH MEDICAL JOURNAL, 1999, 318 (7194) :1324-1327

[3] Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness [J].

Kalra, L ;

Yu, G ;

Perez, I ;

Lakhani, A ;

Donaldson, N .

BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7244) :1236-1239

[4]

LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449

[5]

LAUPACIS A, 1995, CHEST S, V108, P352

[6] National patterns of warfarin use in atrial fibrillation [J].

Stafford, RS ;

Singer, DE .

ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (22) :2537-2541

[7] Prevalence of atrial fibrillation and eligibility for anticoagulants in the community [J].

Sudlow, M ;

Thomson, R ;

Thwaites, B ;

Rodgers, H ;

Kenny, RA .

LANCET, 1998, 352 (9135) :1167-1171

[8]

Teo K, 1998, CAN J CARDIOL, V14, P695

← 1 →